Xin Lang Cai Jing·2025-11-05 02:44Core Viewpoint - Sangfor Technologies experienced a 5.3% decline in stock price, reaching 72.53 CNY per share, with a trading volume of 379 million CNY and a turnover rate of 0.82%, resulting in a total market capitalization of 44.735 billion CNY [1] Company Overview - Sangfor Technologies, established on January 25, 2002, is located in the China (Shanghai) Free Trade Zone. The company was listed on July 22, 2020, and specializes in the research, production, and sales of antibody drugs [1] - The revenue composition of Sangfor Technologies includes 75.24% from product sales, 15.37% from commissioned processing services, 7.94% from licensing services, and 1.44% from leasing services [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Guotai Haitong Asset Management holds a significant position in Sangfor Technologies. The Guotai Haitong Innovative Pharmaceutical Mixed Fund A (014157) held 131,000 shares in the third quarter, accounting for 5.04% of the fund's net value, making it the sixth-largest holding [2] - The Guotai Haitong Innovative Pharmaceutical Mixed Fund A was established on December 23, 2021, with a current size of 1.05 billion CNY. Year-to-date returns are 18.37%, ranking 4465 out of 8150 in its category, while the one-year return is 15.27%, ranking 4673 out of 8043 [2] - The fund manager, Li Zibo, has been in charge for 3 years and 319 days, with a total asset size of 3.067 billion CNY. The best fund return during his tenure is 37.26%, while the worst is -2.87% [2]